Breaking News

Amgen Completes KAI Acquisition

Gains thyroid drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen has completion of the acquisition of KAI Pharmaceuticals based in South San Francisco. The acquisition includes KAI’s lead product candidate KAI-4169, a novel drug being studied for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. The drug has successfully completed a Phase II trial in this indication.    Amgen paid $315 million for KAI in an acquisition announced in April 2012....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters